Abstract
Background Few studies have analyzed the relationship between glucose variability (GV) and adverse health outcomes in patients with differences in glycemic status. The present study tests the hypothesis that GV predicts all-cause mortality regardless of glycemic status after simple (age and sex) and full adjustment (age, sex, cardiovascular disease, hypertension, use of aspirin, statins, GLP-1 receptor agonists, SGLT-2 inhibitors and DPP-4 inhibitors, baseline FPG and average HbA1c).
Methods Prospective cohort study with 795 normoglycemic patients, 233 patients with prediabetes, and 4,102 patients with type 2 diabetes. GV was measured using the coefficient of variation of fasting plasma glucose (CV-FPG) over 12 years of follow-up. The outcome measure was all-cause mortality.
Results A total of 1,223 patients (657 men, 566 women) died after a median of 9.8 years of follow-up, with an all-cause mortality rate of 23.35/1,000 person-years. In prediabetes or T2DM patients, the fourth quartile of CV-FPG exerted a significant effect on all-cause mortality after simple and full adjustment. A sensitivity analysis excluding participants who died during the first year of follow-up revealed the following results for the highest quartile in the fully adjusted model: overall, HR (95%CI) =1.54 (1.26-1.89); dysglycemia (prediabetes and T2DM), HR=1.41 (1.15-1.73); T2DM, HR=1.36 (1.10-1.67).
Conclusion We found CV-FPG to be useful for measurement of GV. It could also be used for the prognostic stratification of patients with dysglycemia.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by Instituto de Salud Carlos III through projects PI15/00259 and PI18/01025 and co-funded by the European Regional Development Fund, A way of shaping Europe.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Institutional Review Board of Ramon y Cajal Hospital, Madrid, for the MADIABETES cohort and the Institutional Review Board of Carlos 3th Hospital, Madrid for the SPREDIA cohort
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵^ Membership of MADIABETES and SPREDIA Consortium is provided in the Acknowledgments.
Data Availability
The data presented in this study are available upon request and after assessment of the request by the corresponding and senior authors. Data are not publicly available owing to restrictions on sharing data in accordance with the consent provided by participants.
Abbreviations
- ADVANCE
- Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation.
- ALLHAT
- Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial.
- CI
- confidence Interval.
- COVID-19
- Coronavirus disease 2019.
- CV-FPG
- coefficient of variation of fasting plasma glucose.
- DBP
- diastolic blood pressure.
- DM
- diabetes mellitus.
- EUROASPIRE
- European Action on Secondary and Primary Prevention by Intervention to Reduce Events.
- FINDRISC
- Finnish Diabetes Risk Score.
- FPG
- fasting plasma glucose.
- GV
- glucose variability.
- HbA1c
- glycated hemoglobin.
- HR
- hazard ratio.
- IGT
- impaired glucose tolerance.
- INDEF
- National Institute of Deaths.
- MAGE
- mean amplitude of glycemic excursions.
- OGTT
- standard oral glucose tolerance test.
- OR
- odds ratio.
- SBP
- diastolic blood pressure
- SD-FPG
- standard deviation of fasting plasma glucose.
- SD-HbA1c
- standard deviation of HbA1c.
- SPREDIA
- Screening prediabetes and type 2 diabetes.
- SPSS
- Statistical Package for the Social Sciences.
- T1DM
- type 1 diabetes mellitus.
- T2DM
- type 2 diabetes mellitus.
- WHO
- World Health Organization.